For the consolidated results of the third quarter of the 2026 fiscal year, net sales were 5,467,679 thousand yen (YoY +10.0%), operating income 1,063,113 thousand yen (+20.0%), ordinary income 1,058,990 thousand yen (+20.4%), and net income attributable to owners of the parent 696,996 thousand yen (+20.8%), showing steady profit growth. In the three segments\u2014real estate brokerage, real estate management, and resident support\u2014both sales and profits increased. The full-year forecast is unchanged from the previous guidance. Capital increase through the issuance of new shares. A significant subsequent event is the completed acquisition of Kyoei Pharmaceutical Research.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"5533","jir_company_name":"Ellitz Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/5533-20260810-01.pdf","jir_short_summary":"For the consolidated results of the third quarter of the 2026 fiscal year, net sales were 5,467,679 thousand yen (YoY +10.0%), operating income 1,063,113 thousand yen (+20.0%), ordinary income 1,058,990 thousand yen (+20.4%), and net income attributable to owners of the parent 696,996 thousand yen (+20.8%), showing steady profit growth. In the three segments\u2014real estate brokerage, real estate management, and resident support\u2014both sales and profits increased. The full-year forecast is unchanged from the previous guidance. Capital increase through the issuance of new shares. A significant subsequent event is the completed acquisition of Kyoei Pharmaceutical Research.","jir_summary":"### Performance Summary\nConsolidated net sales for the third quarter of the current period continued to expand, with operating income, ordinary income, and net income rising above the prior-year period. In the three segments, Real Estate Brokerage, Real Estate Management, and Resident Support demonstrated solid growth, with revenue from properties for sale contributing as well. While personnel and advertising expenses rose, overall cost-cutting effects supported improved profitability. The full-year forecast remains unchanged from the previous projection. Note that the financial summary includes an accounting policy change related to lease contract renewal, which had a minor impact.\n\n### Outlook and Key Trends\nThe full-year earnings outlook remains unchanged from the prior announcement, with continued focus on stable demand for rental brokerage and management in the real estate market, and the synergy from new store openings and new customer acquisition. A significant subsequent event is the completion of the acquisition of Kyoei Pharmaceutical Research, and efforts to expand managed properties and drive cost reductions through in-houseization will continue. Disclosure of rights accrual and acquisition-related costs is also provided, and future integration benefits will be watched closely.","jir_financial_highlights":"Net sales: 5,467,679\u5343\u5186 (YoY +10.0%)\nOperating income: 1,063,113\u5343\u5186 (YoY +20.0%)\nOrdinary income: 1,058,990\u5343\u5186 (YoY +20.4%)\nNet income attributable to owners of parent: 696,996\u5343\u5186 (YoY +20.8%)\nEquity ratio: 58.0% (vs prior term\/3Q end)","jir_category":"","jir_hashtags":"#EllitzHoldings, #Earnings, #RealEstateIndustry, #FinancialHighlights","jir_key_figures":"Net sales: 5,467,679\u5343\u5186 (YoY +10.0%)\nOperating income: 1,063,113\u5343\u5186 (YoY +20.0%)\nNet income attributable to owners of parent: 696,996\u5343\u5186 (YoY +20.8%)","jir_meta_title":"Ellitz Holdings 2026 Fiscal Year Third Quarter Financial Results | Net sales 5,467,679 thousand yen, Operating income 1,063,113 thousand yen","jir_meta_description":"Key points of Ellitz Holdings' Q3 FY2026 financial results. Increases in net sales and profits, segment growth, maintenance of full-year guidance, completion of the acquisition of Kyoei Pharmaceutical Research, and more.","jir_og_title":"Ellitz Holdings Announces Third Quarter Results","jir_og_description":"Ellitz Holdings' Q3 results show net sales up 10% YoY and substantial gains in operating and net income. Summary of key topics including completion of the Kyoei Pharmaceutical Research acquisition.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2025 Q3\\\",\\\"FY2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net sales (thousand yen)\\\",\\\"data\\\":[4972734,5467679],\\\"borderColor\\\":\\\"rgb(75,192,192)\\\",\\\"fill\\\":false}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2025 Q3\\\",\\\"FY2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating income (thousand yen)\\\",\\\"data\\\":[885841,1063113],\\\"borderColor\\\":\\\"rgb(54,162,235)\\\",\\\"fill\\\":false}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Real Estate Brokerage\\\",\\\"Real Estate Management\\\",\\\"Resident Support\\\"],\\\"datasets\\\":[{\\\"data\\\":[2893420,1927604,646654],\\\"backgroundColor\\\":[\\\"#FF6384\\\",\\\"#36A2EB\\\",\\\"#FFCE56\\\"]}]}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profit Margin\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Real Estate Brokerage\\\",\\\"Real Estate Management\\\",\\\"Resident Support\\\"],\\\"datasets\\\":[{\\\"data\\\":[607366,337441,371184],\\\"backgroundColor\\\":[\\\"#4BC0C0\\\",\\\"#9966FF\\\",\\\"#FF9F40\\\"]}]}\"}]","ir_related_company":59593,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-100442","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n